In 1990s, murine studies and clinical trials suggested that IL-2 therapy after autologous HSCT or T-cell depleted allogeneic HSCT could modulate GVHD without reducing the GVL activity (11–15). The gene discussed is IL2; the disease is graft versus host disease.